Evidence map›Paper›PMID 23296188›Full record

ArticleNeuroImage2013

Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features.

Boris A Gutman, Xue Hua, Priya Rajagopalan, Yi-Yu Chou, Yalin Wang, Igor Yanovsky, Arthur W Toga, Clifford R Jack, Michael W Weiner, Paul M Thompson and 1 more

Abstract read
In one paragraph

Article in NeuroImage, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. A 3D Brain Geometry Toolkit for Multisite Neuroimaging Analysis.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. APPROXIMATING PRINCIPAL GENETIC COMPONENTS OF SUBCORTICAL SHAPE.Proceedings. IEEE International Symposium on Biomedical Imaging · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Boris A GutmanImaging Genetics Center, Laboratory of Neuro Imaging, Dept. of Neurology, UCLA School of Medicine, Los Angeles, CA 90095-1769, USA.
Xue Hua
Priya Rajagopalan
Yi-Yu Chou
Yalin Wang
Igor Yanovsky
Arthur W Toga
Clifford R Jack
Michael W Weiner
Paul M Thompson
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI RAJAN, KUMAR B. · 1991 to 2020
$28.3M
UCLA ALZHEIMERS DISEASE RESEARCH CENTERP50AG016570 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRILL, JOSHUA · 1999 to 2014
$25.9M
Alzheimer's disease risk analyzed using population imaging genomicsR01AG040060 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2011 to 2016
$2.5M
DIGITAL REPRESENTATION AND VISUALIZATION OF HUMAN BRAINR01LM005639 · NLM · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TOGA, ARTHUR W · 1995 to 2005
$1.8M
"MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies"K01AG030514 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARMICHAEL, OWEN T. · 2008 to 2012
$495k
Novel PDEs for Cortical Mapping and Analysis in DiseaseR21RR019771 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI THOMPSON, PAUL M · 2003 to 2004
$351k
CIHRNCRR NIH HHS R21 RR019771NCRR NIH HHS RR019771NIA NIH HHS AG016570NIA NIH HHS K01 AG030514NIA NIH HHS P30 AG010129NIA NIH HHS P50 AG016570NIA NIH HHS R01 AG040060NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG010483NIBIB NIH HHS EB01651NLM NIH HHS LM05639NLM NIH HHS R01 LM005639
6 · The paper itself

Abstract

We propose a new method to maximize biomarker efficiency for detecting anatomical change over time in serial MRI. Drug trials using neuroimaging become prohibitively costly if vast numbers of subjects must be assessed, so it is vital to develop efficient measures of brain change. A popular measure of efficiency is the minimal sample size (n80) needed to detect 25% change in a biomarker, with 95% confidence and 80% power. For multivariate measures of brain change, we can directly optimize n80 based on a Linear Discriminant Analysis (LDA). Here we use a supervised learning framework to optimize n80, offering two alternative solutions. With a new medial surface modeling method, we track 3D dynamic changes in the lateral ventricles in 2065 ADNI scans. We apply our LDA-based weighting to the results. Our best average n80-in two-fold nested cross-validation-is 104 MCI subjects (95% CI: [94,139]) for a 1-year drug trial, and 75AD subjects [64,102]. This compares favorably with other MRI analysis methods. The standard "statistical ROI" approach applied to the same ventricular surfaces requires 165 MCI or 94AD subjects. At 2 years, the best LDA measure needs only 67 MCI and 52AD subjects, versus 119 MCI and 80AD subjects for the stat-ROI method. Our surface-based measures are unbiased: they give no artifactual additive atrophy over three time points. Our results suggest that statistical weighting may boost efficiency of drug trials that use brain maps.

Indexed as

AgedAlzheimer DiseaseCerebral VentriclesCognitive DysfunctionDiscriminant AnalysisDisease ProgressionFemaleHumansMagnetic Resonance ImagingMale

Identifiers

PMID23296188
PMCPMC3942253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.